Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Trial details
- Registry ID
- NCT05232916
- Drugs studied
- GLSI-100
TrialRedline tracks 1 clinical trial sponsored by Greenwich LifeSciences, Inc.: 1 Phase 3.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsNCT05232916 | GLSI-100 | Recruiting | 2031-12Estimated |
Names as written in the registry records.
NCT05232916 · Greenwich LifeSciences, Inc.
Before: 750 participants (planned). After: 2250 participants (planned).
Before: Dec 2026. After: Dec 2031.